Cargando…

Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis

BACKGROUND: To identify possible differences in cardiovascular (CV) risk among different insulin therapies, we performed pre-specified meta-analyses across the clinical program for basal insulin peglispro (BIL), in patients randomized to treatment with BIL or comparator insulin [glargine (IG) or NPH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoogwerf, Byron J., Lincoff, A. Michael, Rodriguez, Angel, Chen, Lei, Qu, Yongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869328/ https://www.ncbi.nlm.nih.gov/pubmed/27188479 http://dx.doi.org/10.1186/s12933-016-0393-6

Ejemplares similares

The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes
por: Orchard, Trevor J., et al.
Publicado: (2017)

Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: IMAGINE 2 randomized trial
por: Davies, M. J., et al.
Publicado: (2016)

Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials
por: Rosenstock, Julio, et al.
Publicado: (2016)

Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3
por: Bergenstal, R. M., et al.
Publicado: (2016)

How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes
por: Muñoz-Garach, Araceli, et al.
Publicado: (2016)

Randomized double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4
por: Blevins, T., et al.
Publicado: (2016)

Open‐label, randomized study comparing basal insulin peglispro and insulin glargine, in combination with oral antihyperglycemic medications, in insulin‐naïve Asian patients with type 2 diabetes
por: Hirose, Takahisa, et al.
Publicado: (2017)

Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8
por: Harris, Cynthia, et al.
Publicado: (2017)

Comparison of Mortality and Major Cardiovascular Events Among Adults With Type 2 Diabetes Using Human vs Analogue Insulins
por: Neugebauer, Romain, et al.
Publicado: (2020)

Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial
por: Schwartz, Gregory G., et al.
Publicado: (2021)

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes
por: Bergenstal, Richard M., et al.
Publicado: (2012)

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
por: Ratner, Robert, et al.
Publicado: (2011)

Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus
por: Fu, Liyao, et al.
Publicado: (2021)

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy
por: Tobin, G S, et al.
Publicado: (2012)

Waist circumference is associated with major adverse cardiovascular events in male but not female patients with type-2 diabetes mellitus
por: Xing, Zhenhua, et al.
Publicado: (2020)

Association of Prior Intracerebral Hemorrhage With Major Adverse Cardiovascular Events
por: Gaist, David, et al.
Publicado: (2022)

Cardiovascular effects of basal insulins
por: Mannucci, Edoardo, et al.
Publicado: (2015)

Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study
por: Longato, Enrico, et al.
Publicado: (2021)

Insulin glargine versus other types of basal insulin–clinical and tumor characteristics in patients with breast carcinoma
por: Besic, Nikola, et al.
Publicado: (2013)

Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk
por: Huang, Wan-Chun, et al.
Publicado: (2021)

Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: a 7-year follow-up study
por: Blanc-Bisson, C., et al.
Publicado: (2018)

Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis
por: D’Andrea, Elvira, et al.
Publicado: (2020)

FRI117 Major Adverse Cardiovascular Events In Severe Insulin Resistance Syndromes: Lipodystrophy Compared To Pathogenic Variants Of The Insulin Receptor
por: Lightbourne, Marissa, et al.
Publicado: (2023)

Response to Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes. Diabetes Care 2012;35:2140–2147
por: Bergenstal, Richard M., et al.
Publicado: (2013)

Cardiac rehabilitation performance predicts 1‐year major adverse cardiovascular events
por: Naami, Robert, et al.
Publicado: (2022)

Cardiovascular safety of long‐acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?
por: Chang, Chia‐Hsuin, et al.
Publicado: (2017)

Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study
por: Pawaskar, Manjiri, et al.
Publicado: (2013)

Four‐year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation
por: Miao, Benjamin, et al.
Publicado: (2020)

Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
por: Bajaj, Harpreet S, et al.
Publicado: (2023)

Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data
por: Young, James B., et al.
Publicado: (2018)

Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14
por: Pratley, Richard E., et al.
Publicado: (2019)

Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
por: Yoon, Kun-Ho, et al.
Publicado: (2017)

Adverse cardiovascular outcomes between insulin-treated and non-insulin treated diabetic patients after percutaneous coronary intervention: a systematic review and meta-analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2015)

Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals
por: Meloni, Alison R, et al.
Publicado: (2013)

Effects of background statin therapy on glycemic response and cardiovascular events following initiation of insulin therapy in type 2 diabetes: a large UK cohort study
por: Anyanwagu, Uchenna, et al.
Publicado: (2017)

Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump
por: Boronat, Mauro, et al.
Publicado: (2015)

Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes
por: Berard, Lori, et al.
Publicado: (2018)

Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
por: Moreira, Rodrigo Oliveira, et al.
Publicado: (2018)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Elevated levels of adiponectin associated with major adverse cardiovascular and cerebrovascular events and mortality risk in ischemic stroke
por: Tu, Wen-Jun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gchjuqqhpvunf7c29ki0kq38i4